This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
“I am happy to welcome Patrick to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He has deep expertise in medical...
New targeted therapies have extended survival, improved quality of life, and enabled more personalized treatment decisions based on genetic risk factors, age,...
CRA is a proud sponsor of the event for market access, reimbursement, and government policy experts. Ashley Fraser presents on “MFN – Implications in...
CRA is a proud sponsor of the event. Josh Sherman is a panelist during the session titled “Global antitrust trends reshaping the life sciences market”...
